Morphotek, Inc.

Morphotek, Inc. is no longer an independent company. It was acquired by Eisai Co., Ltd., a Japanese pharmaceutical company, in 2011. Therefore, information about Morphotek as a standalone entity is limited. To understand its current activities and contributions, one must look at Eisai's operations. Eisai's website (https://us.eisai.com/) provides details on its current research, development, and product portfolio. While the website does not explicitly detail Morphotek's contributions as a separate entity post-acquisition, it's reasonable to assume that Morphotek's technology and expertise in areas like antibody engineering have been integrated into Eisai's overall research and development efforts. Specifically, Morphotek was known for its expertise in antibody technology, including its proprietary "MORPHODOMINANT™" technology platform. This technology likely contributes to Eisai's current research and development of various therapies, though the extent of that contribution is not publicly specified in detail on Eisai's website. In summary, Morphotek's legacy is now part of Eisai's broader biopharmaceutical operations.